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TO THE EDITOR
Myelodysplastic syndrome (MDS) is an acquired clonal stem cell disorder, often associated with a variety of chromosomal abnormalities. The presence of certain abnormal karyotypes at diagnosis is associated with a greater probability of transformation into acute myeloid leukemia (AML), 1 with a notoriously poor response to conventional chemotherapy. The Philadelphia chromosome (Ph) is generated by a specific translocation involving chromosomes 9 and 22, and is found in 95% of patients with chronic myeloid leukemia (CML) and some acute leukemias. The resultant BCR-ABL mRNA encodes the BCR-ABL oncoprotein, which has greatly enhanced tyrosine kinase activity and a central role in the pathogenesis of these disorders. 2 Imatinib mesylate, a novel tyrosine kinase inhibitor selective for the BCR-ABL oncoprotein, has recently been shown to be effective in CML with some patients achieving complete cytogenetic remissions. 3 Ph+ MDS is uncommon, with less than 20 cases described in the literature worldwide, 4 and responds poorly to conventional chemotherapy. Here, we report the first case of Ph+ MDS successfully treated with the novel tyrosine kinase inhibitor imatinib mesylate.
A 67-year-old woman presented in April 1999 with mild pancytopenia: hemoglobin 115 g/l, WBC 3.4 × 10 9 /l (neutrophils 1.2, lymphocytes 1.6, basophils 0.0, eosinophils 0.1, blasts 0.3 and myelocytes 0.2 ϫ 10 9 /l) and platelets 111 × 10 9 /l. Blood smear examination revealed anisopoikilocytosis and hypogranulated pseudo Pelger-Huët neutrophils. There was no splenomegaly or lymphadenopathy on examination. LDH was elevated at 1163 U/l (normal range 80-180 U/l). Assays for vitamin B12 and folate were within normal ranges. Bone marrow (BM) smear at diagnosis showed a myeloid: erythroid ratio of 3:1, marked trilineage dysplasia and 10% blasts on a 500 cell differential count. Overall cellularity was moderately increased, with stainable iron present. Dyserythropoiesis was prominent with multinucleated cells, internuclear bridging and megaloblastoid nuclei. No ringed sideroblasts were seen. Frequent hypolobulated micromegakaryocytes were observed, with occasional bizarre nuclear patterns in larger forms. The disorder was classified as de novo MDS, subtype refractory anemia with excess blasts type 2 (RAEB-2), accord- ing to the WHO Classification of Tumours.
5 BM cytogenetics at diagnosis showed 29/30 Ph+ and 1/30 46XX metaphases with no additional karyotypic abnormalities. Serial blood films demonstrated early disease progression (a rise in the percentage of blasts from 9% to 20%), and treatment was commenced (comprising daunorubicin 50 mg/m 2 for 3 days and cytosine 100 mg/m 2 bd for 8 days). The marked reduction in percentage of Ph+ metaphases (to 6%) and blasts (to 3%) and improvement in BM dysplastic features observed after the first cycle were not sustained (Figure 1 ), despite two further cycles of chemotherapy followed by a trial of ␣-interferon (IFN, commenced in view of the Ph+ status). Serial BM examinations thereafter showed a progressive increase in the blast population. Prior to commencing imatinib, a repeat BM showed 22% blasts, ongoing features of triline-
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Figure 2
Characterization of BCR-ABL mRNA by PCR (a). Lane 1: patient sample pre-imatinib. ) was negative, as performed at two independent centers using both the Light-Cycler and BCR-ABL detection kit (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's instructions, and the TaqMan system. Nested PCR for BCR-ABL was negative using the methodology of Cross et al 7 (data not shown). At 14 months from commencement of imatinib, BCR-ABL transcripts remained undetectable by all methods (data not shown). RNA for RT-PCR (sensitivity 1 BCR-ABL positive cell in 10 5 ) and Q-RT-PCR on the Light Cycler was extracted from 20 ml peripheral blood using TRIzol (Life Technologies) according to the manufacturer's instructions, and cDNA manufactured using the Reverse-iT 1st Strand Synthesis Kit (Abgene, Epsom, UK). Primers used for RT-PCR: c-ABL -TTCAGCGGCCAGTAGCATCTGACTT (forward) and CCAGGAGTGTTT CTCCAGACTG (reverse), BCR -GAAGAAGTGTTTCAGAAGCTTCT CCC (forward). RNA and cDNA for TaqMan and nested PCR was prepared as previously described. 7 Using TaqMan the BCR-ABL and ABL mRNA levels were quantified by subjecting 5 l of cDNA to 50 cycles of PCR using the Applied Bisosytems 7700 Sequence Detection System (Foster City, CA, USA) and the TaqMan Universal Master Mix in accordance with the manufacturers instructions, in a final reaction volume of 25 l. Standard TaqMan cycling conditions were used to amplify the cDNA ie 7700 SDS de-fault settings. Optimum probes and primer were selected using the Primer Express software (Applied Biosystems). Analysis of clonality by X-inactivation at the HUMARA locus (b). The HUMARA assay was performed as previously described (except peak areas rather than peak heights were analyzed 8 ), using stored marrow from diagnosis and positively selected T cells and granulocytes (from peripheral blood) after 7 months treatment with imatinib. DNA from stored, pre-treatment BM showed clonal hemopoiesis (larger:smaller band ratio Ն4.36), with restoration of polyclonal hemopoiesis after imatinib treatment (peripheral blood T cell and granulocytic ratios 1.0 and 1.12, respectively).
age MDS and 100% Ph positivity (30/30 metaphases) as an isolated cytogenetic abnormality. Splenomegaly remained absent and there was moderate pancytopenia. After obtaining written informed consent, and with the approval of the local Research and Ethics Committee, imatinib was commenced in April 2001 (23 months after diagnosis) at a dose of 600 mg daily. Transient grade 3 neutropenia and grade 2 thrombocytopenia and anemia (NCI/NIH common toxicity criteria) occurred in the first 10 weeks of therapy, and required transfusion of 2 units of packed red cells. Treatment was continued throughout these episodes. BM cytogenetics performed after 3 months of imatinib therapy showed a normal female karyotype and the absence of the Ph chromosome in all 30 metaphases examined. BM morphology showed hypercellular granules with a reversed M:E ratio of 1:2. Only minor residual dysplastic changes were observed (primarily in the myeloid series) and blasts were absent. BCR-ABL mRNA was undetectable by RT-PCR (Figure 2a) , sensitive quantitative RT-PCR at 4, 7 and 14 months (27, 30 and 37 months from diagnosis, respectively) after commencing imatinib treatment (confirmed at two independent centers, data not shown), and by nested PCR (see legend to Figure 2 ). To exclude Ph-negative MDS we carried out clonality analysis using the HUMARA assay (Figure 2b ), which confirmed a return to a polyclonal state. Currently, the patient has mild pancytopenia (Hb 118 g/l, WCC 3.6 ϫ 10 9 /l and platelets 117 × 10 9 /l unsupported) on 600 mg/day imatinib and remains well.
We have described, as far as we are aware, the first case of Ph+ MDS successfully treated with imatinib mesylate resulting in a complete molecular remission by nested PCR. The median survival of patients with RAEB-2 is only 10 months, 6 and conventional therapy, although initially successful, was followed by a rapid return to a Ph+ state. Molecular characterization of the BCR-ABL fusion transcript demonstrated the b2a2 form, as commonly found in typical CML. Despite this there were no myeloproliferative features, and the clinical picture was otherwise of classical MDS, subtype RAEB-2. Despite a total of eight BM cytogenetic preparations, no other karyotypic abnormalities were seen. The response to imatinib was similar, in our experience, to many chronic phase CML patients achieving a complete cytogenetic response: an initial fall in blood counts to a nadir followed by slow recovery. The rise in counts presumably reflects the recovery of Ph-negative stem cells. It should be emphasized that sustained molecular remissions in imatinib-treated CML patients using our sensitive Taq-man methodology are rare (JK, unpublished observations). Additionally, to exclude an underlying residual dysplastic state with a successfully treated Ph+ subclone, we performed the HUMARA assay on DNA pre-and post treatment with imatinib, and demonstrated a return to a polyclonal state. Given the poor outcomes of such cases in the literature, to date, we would therefore advocate imatinib mesylate as an effective treatment for this rare malignancy. 
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TO THE EDITOR
Imatinib mesylate (STI571, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, created by the Philadelphia translocation, t(9;22)(q34;q11) (Ph+) of chronic myeloid leukemia (CML). In the first studies, the drug appears to be very effective and generally well tolerated, 1-3 but as it is only recently introduced, few data are available about long-term effects, specifically the possibility of secondary malignancies. Recently, several patients have been noticed to develop clonal karyotype abnormalities in Philadelphia translocation negative cells (Ph−). [4] [5] [6] [7] Since November 2000 we studied 274 patients treated with Imatinib in chronic-phase CML resistant and/or intolerant to interferon ␣, accelerated phase and blast crisis. Cytogenetic data at onset of treatment and at least one follow-up are available for 200 cases. Four patients who achieved complete or major response show persistent clonal abnormalities in their Ph− cells.
We compared this with our historical population of patients with CML, studied between 1 January 1990 and 9 November 2001, treated according to different protocols. 434 patients were studied, 227 remained 100% Ph+. 207 had (partial) cytogenetic remissions. Of this last group, three had non-clonal abnormalities and two had clonal, but transient abnormalities in the Ph− clone.
Case 1: A woman was diagnosed with CML, in September 1999, at the age of 37. Initial treatment with interferon ␣ and cytarabine failed and imatinib (400 mg daily) was started in November 2000. Bone marrow cytogenetics evolved from 100 % Ph+ (46,XX,t(9;22;20)(q34;q11;q11) [20] ) to 52% at 6 months (Table 1) .
Clinically she is in hematologic remission and there is no evidence of myelodysplastic syndrome (MDS), only of macrocytosis, which is not unusual during any cytotoxic therapy.
Case 2: A man was diagnosed with CML in 1994 at the age of 37. He became refractory to interferon ␣, and had an autologous transplant in accelerated phase, 4 years ago. He was maintained in hematologic response with interferon ␣, with 100% Ph+ mitoses (46,XY,t(9;22)(q34;q11) [30] ). In December 2000 treatment with imatinib (400 mg daily) was started for CML in acceleration. After 3 months he presented with pancytopenia and myelodysplastic features in the bone marrow. The karyotype was 46,XY,t(9;22)(q34;q11) [4] /45,XY,−7 [3] . After 6 and 9 months therapy all cells showed trisomy 8 (47,XY,+8 [20] ). An isolated t(4;8)(q22;p22) appeared in one mitosis on three separate occasions, in two on his last check up. The last three occurrences were after starting imatinib. Clinically he is in remission, without signs of MDS.
We present four patients with sustained clonal abnormalities in Ph− cells during imatinib therapy.
Two patients developed two abnormal clones characterized by trisomy 8 and monosomy 7: in case 1 monosomy 7 was prevalent and in case 2 it was the trisomy 8 (Table 1) . Trisomy 8 is a non random abnormality most frequent in myeloproliferative disorders, including CML, while monosomy 7 is more related to secondary MDS and AML.
In two other cases, the abnormal clone is characterized by unusual translocations which were found already in one cell (therefore not clonal) after interferon ␣ treatment. After imatinib, these Ph− aberrant clones persisted and seemed to gain in importance. The emergence of clonal aberrations in the Ph− cell population, after interferon ␣ therapy has also been reported (reviewed in Ref. 6 ). The persistence (and increase) of the abnormality after imatinib confirms the clonality of the cytogenetic change.
Very recently, Andersen et al 6 reported similar observations, reviewed the literature and discussed the possible mechanisms. We agree with these authors that the proliferative advantage of the Ph+ cells may have masked a pre-existing aberration. On the other hand, these patients were heavily pretreated which may have induced these cytogenetic changes. 5 In addition, it cannot be excluded that imatinib has a role in mutagenesis or immune suppression. All these possibilities need further examination. Whether these new Ph− aberrant clones, not sensitive to imatinib will herald a new pathology (MDS, AML) await further follow-up. In our series, up until now, only case 2 shows actual MDS (with some reservations because of the ongoing treatment with imatinib), but close follow-up is needed.
The frequency of this phenomenon is relatively high after imatinib and is probably due to the efficacy of the drug in suppressing the Ph+ clone
